SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is actively trending due to significant community discussion surrounding a recent high-profile speech by Donald Trump, with reactions split between praise for his rhetoric and strong criticism for alleged lies and divisive commentary. This speech, which also reignited conversations around tariffs and past controversies, is sparking polarized debate among retail investors regarding the stock's future trajectory.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending due to upcoming earnings and intense debate surrounding the CLARITY Act's impact on stablecoin yields, with bulls highlighting growing institutional adoption and USDC's foundational role while bears cite regulatory uncertainty, past insider selling, and its price correlation to broader crypto market volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following its CEO's significant presentation at a major cancer summit outlining breakthroughs in 'chemo-free' treatments and recent international regulatory approvals for its ANKTIVA therapy. The community is actively discussing the stock's "unstoppable" scientific progress and the potential for a substantial short squeeze fueled by high short interest.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending as the community highlights its recent Japanese PMDA approval for the Alpha DaRT cancer treatment, viewing this critical regulatory validation as a catalyst for significant global commercial expansion and increased institutional attention.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is a top trend as the market eagerly anticipates its upcoming earnings, with community discussion intensely focused on whether the results will propel the broader AI sector and major indices or lead to a "sell the news" reaction, amplified by recent headlines about US-China chip export restrictions.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending amid an escalating bidding war for Warner Bros. Discovery, as its revised, all-cash offer has been deemed a "Company Superior Proposal" by WBD's board, forcing Netflix to potentially match or cede the deal while the community debates regulatory risks and the substantial debt involved.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending following strong Q4 Tyvaso DPI sales that showed accelerating growth and increased market penetration, with the community eagerly anticipating its upcoming full-year earnings report and potential catalysts like pediatric Afrezza approval. Investors are discussing whether these positive revenue trends and future pipeline developments will overcome historical concerns regarding Afrezza's performance and alleged stock manipulation to drive sustained share price growth.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is trending due to its successful pivot into AI data center infrastructure, highlighted by a substantial $7 billion, 15-year deal for its River Bend project with a major hyperscaler. The community largely applauds this strategic shift, noting HUT's strong performance and resilience compared to other crypto-exposed companies amidst market fluctuations.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending after its recent financial earnings report showed robust revenue growth from new restaurant openings and spurred analyst price target hikes, despite moderated same-store sales. Community sentiment is sharply divided, with bulls touting its growth story and expansion potential, while bears actively debate its high valuation multiples and tight operating margins compared to industry peers.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing a significant sell-off, driven by weaker-than-expected fiscal year 2027 subscription revenue guidance and broader market fears of AI disruption impacting the enterprise software sector. Despite beating recent earnings, community discussion highlights contrasting views on whether the downturn is an overreaction, particularly as major AI companies like OpenAI and Anthropic reportedly utilize Workday's own software.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Announces Closing of Oversubscribed Private Placement Financing Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire NEW YORK, Feb. 17, 2026 Upfront Proceeds of...

Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...

D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00

D. Boral Capital cut their price target on shares of Immunic from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Friday...

<ul class="summary-bullets"><li>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs.</li><li>The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.</li><li>Immunic looks to prioritize its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026.</li></ul>Immunic Inc. (IMUX) announced on Friday that it has secured a private placement that could generate up to $400 million in gross proceeds, providing funding to advance its multiple sclerosis programs and support future product launches.The financing, led by existing investor BVF Partners and including several institutional backers, includes $200 million in upfront proceeds and the potential for an additional $200 million if warrants are exercised.&nbsp;The transaction is expected to close around February 17, pending customary conditions.<h2 class="st-heading-2">Financing To Advance Clinical Studies</h2>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs. Together with its existing cash and investments, the funds are expected to cover operating and capital costs through the end of 2027.The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/IMUX">Immunic stock</a> traded over 33% higher in Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h2 class="st-heading-2">Multiple Sclerosis Programs Take Priority&nbsp;</h2>Immunic plans complete its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026. The company aims to file a New Drug Application in mid-2027 and, if approved, launch in 2028. It also intends to initiate a Phase 3 program in primary progressive multiple sclerosis later this year, a trial projected to run up to four years.<blockquote>“The proceeds from the initial closing are expected to provide sufficient runway through submission of an NDA in the United States in mid-2027 and to start preparations for the potential launch of vidofludimus calcium in RMS, as well as initiation of a phase 3 clinical program in PPMS.”-Daniel Vitt, CEO, Immunic</blockquote>Vitt will begin a search for a CEO to lead the next phase of growth. Vitt plans to transition into a senior strategic role while remaining on the board.IMUX stock has declined by 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aap-stock-surges-pre-market-what-s-fueling-the-rally/cZR5s0pR4sw">AAP Stock Surges 9% Pre-Market – What’s Fueling the Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IMUX Stock Surge 33% Pre-Market Today? 

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.  

Equity

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company Immunic Announces Oversubscribed Private Placement of up to USD...

HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)

HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Immunic in a research report on Monday...

Brookline Cap M Predicts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Brookline Cap M issued their FY2025 EPS estimates for shares of Immunic in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M...

Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M

Brookline Cap M raised shares of Immunic to a "strong-buy" rating in a research note on Tuesday...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMUX News

IMUXImmunic Inc